darunavir has been researched along with Nervous System Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arduino, I; Curri, ML; Denora, N; Depalo, N; Fanizza, E; Laquintana, V; Latronico, T; Liuzzi, GM; Mastroianni, CM; Milella, S; Panniello, A; Rizzi, F; Striccoli, M | 1 |
| Hill, A; Moecklinghoff, C; Winston, A | 1 |
2 other study(ies) available for darunavir and Nervous System Diseases
| Article | Year |
|---|---|
Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.
Topics: Brain; Darunavir; HIV Infections; Humans; Matrix Metalloproteinase 9; Nanoparticles; Nervous System Diseases | 2021 |
Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Ritonavir; Sulfonamides | 2012 |